Human antibodies against eotaxin
View Patent ↗Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibody VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT-213. One or more complementarity determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CDR3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
1. A specific binding member that binds human eotaxin and which comprises an antibody VH domain which comprises a VH CDR1, a VH CDR2 and a VH CDR3, wherein said VH CDR1, VH CDR2 and VH CDR3 consist of the amino acid sequences of SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7, respectively,
and which further comprises an antibody VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3.
2. A specific binding member according to claim 1 comprising the CAT-212 VH domain (SEQ ID NO. 2).
3. A specific binding member according to claim 1 wherein the VL CDR3 consists of the amino acid sequence of SEQ ID NO. 10.
4. A specific binding member according to claim 3 wherein the VL CDR1 and VL CDR2 consist of the amino acid sequences of SEQ ID NOS. 8 and 9 respectively.
5. A specific binding member according to claim 1 wherein the antibody VL domain is the CAT-212 VL domain (SEQ ID NO. 4).
6. A specific binding member according to claim 1 that binds eotaxin with affinity equal to or better than the affinity of an eotaxin antigen-binding site formed by the CAT-212 VH domain (SEQ ID NO. 2) and the CAT-212 VL domain SEQ ID NO. 4), the affinity of the specific binding member and the affinity of the antigen-binding site being as determined under the same conditions.
7. A specific binding member according to claim 1 that neutralises eotaxin.
8. A specific binding member according to claim 7 that neutralises eotaxin with a potency equal to or better than the potency of an eotaxin antigen-binding site formed byte CAT-212 VH domain (SEQ ID NO. 2) and the CAT-212 VL domain (SEQ ID NO. 4), the potency of the specific binding member and the potency of the antigen-binding site being as determined under the same conditions.
9. A specific binding member according to claim 1 that comprises an scFv antibody molecule.
10. A specific binding member according to claim 1 that comprises an antibody constant region.
11. A specific binding member according to claim 10 that comprises a whole antibody.
12. A specific binding member according to claim 10 or claim 11 comprising an lgG4 constant region.
13. The specific binding member according to claim 1 , wherein the specific binding member competes for binding to eotaxin with an eotaxin-binding domain of an antibody comprising the CAT-212 VH domain (SEQ. ID NO 2) and the CAT-212 VL domain (SEQ ID NO. 4).